

姓名:	李懿宸	填表日期: (YYYY/MM/DD)	2023/02/21	
單位:	內科部胃腸肝膽科	現職職稱:	主治醫師	
Email:	iclee@vghtpe.gov.tw	連絡電話:	02-28757506	
學歷:	國立陽明大學醫學系 學士 1997-2004 國立陽明大學臨床醫學研究所 博士 2011-2014			
重要經歷:	國立陽明大學附設醫院內科部主治醫師 2012-2014 臺北榮民總醫院內科部胃腸肝膽科主治醫師 2014~			
研究方向: (關鍵詞)	Clinical and translational researches of chronic hepatitis B and HCC, particularly host immune regulators and viral factors in the pathogenesis, natural history and outcomes of chronic hepatitis B and HCC. Application of artificial intelligence in HCC.			
五年內 代表著作:	<ol style="list-style-type: none"> 1. Lee IC*, et al. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib. <i>Viruses</i> 2022 Oct 26;14(11): 2355. 2. Lee IC*, et al. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. <i>Int J Mol Sci.</i> 2022 Sep 26;23(19):11335. 3. Lee IC, et al. Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. <i>Cancers (Basel).</i> 2022 Apr 15;14(8):2014. 4. Chi CT, Lee IC, et al. Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. <i>Cancers (Basel).</i> 2021 Aug 27;13(17):4325. 5. Lee IC, et al. Evolutionary Learning Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma After Resection. <i>Liver Cancer.</i> 2021 Sep 20;10(6):572-582. 6. Chen MH*, Lee IC, et al. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in rheumatic patients. <i>Ann Rheum Dis.</i> 2021 Nov;80(11):1393-1399. 7. Wu KC, Lee IC*, et al. Comparable Benefits of HCV Eradication by Direct Acting Antivirals and Interferon-based Therapy in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. <i>Am J Cancer Res.</i> 2021 Nov 15;11(11):5526-5542. 8. Hung YW, Lee IC*, et al. Redefining Tumor Burden in Patients with Intermediate Stage Hepatocellular Carcinoma: the Seven-Eleven Criteria. <i>Liver Cancer.</i> 2021 Jul 22;10(6):629-640. 9. Lee IC, et al. Predictors of Long-term Recurrence and Survival After Resection of HBV-related Hepatocellular Carcinoma: The Role of HBsAg. <i>Am J Cancer Res.</i> 2021 Jul 15;11(7):3711-3725. 			

五年內
代表著作(續)

10. **Lee IC**, et al. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc. 2021 Sep;120(9):1676-1685.
11. Wu CJ, Chau GY, **Lee IC**, et al. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. J Formos Med Assoc. 2021 Aug;120(8):1563-1571.
12. **Lee IC***. Immunotherapy for hepatocellular carcinoma: The challenge of biomarker studies. J Chin Med Assoc. 2021 Feb 1;84(2):121-122.
13. Liu CA, **Lee IC**, et al. Prediction of survival according to kinetic changes of cytokines and hepatitis status following radioembolization with yttrium-90 microspheres. J Formos Med Assoc. 2021 Apr;120(4):1127-1136.
14. **Lee IC**, et al. Cessation of Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Taiwan: Risky but Inevitable. J Chin Med Assoc. 2020 Jun;83(6):515-516.
15. **Lee IC**, et al. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020 Jun;83(6):521-523.
16. **Lee IC**, et al. A New ALBI-based Model to Predict Survival After Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma. Liver Int. 2019 Sep;39(9):1704-1712.
17. Young SH, Chau GY, **Lee IC**, et al. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. J Formos Med Assoc. 2020 Jan;119(1 Pt 2):218-229.
18. **Lee IC**, et al. Risk of Renal Events During Tenofovir Disoproxil Fumarate and Entecavir Antiviral Prophylaxis in HBsAg-Positive Cancer Patients Undergoing Chemotherapy. J Viral Hepat. 2018 Dec;25(12):1599-1607.
19. **Lee IC**, et al. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. J Infect Dis. 2018 Aug 24;218(7):1075-1084.

研究室成員: 黃振哲